Compare Adaptive Biotechnologies Corp (ADPT) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Lamb Weston Holdings Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.9 (market cap $3.33B), while Lamb Weston Holdings Inc trades at $46.42 (market cap $6.42B). The key difference: Lamb Weston Holdings Inc is the larger of the two by market cap, and Lamb Weston Holdings Inc pays a 3.27% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | LW | |
|---|---|---|
Market Cap | $3.33B | $6.42B |
Sector | Health | Consumer Staples |
52-Week High | $22.37 | $66.57 |
52-Week Low | $10.24 | $38.48 |
Enterprise Value | $3.19B | $10.39B |
Dividend Yield | — | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Lamb Weston (LW) trades at $46.51, up 1.31% on the day, with a bullish technical signal and consistent earnings beats. The company reported Q1 2026 EPS of $0.72, exceeding the $0.626 estimate, and maintains a P/E of 21.64 and P/S of 0.99. Recent news highlights its 'Focus to Win' strategy driving North America volume gains and cost savings, while activist investors like Starboard Value push for operational improvements.
The outlook is cautiously optimistic, supported by earnings momentum and strategic initiatives, but risks include a class-action lawsuit, margin pressures, and high debt levels. Analyst consensus is mixed with 35% buy ratings, reflecting balanced sentiment amid turnaround efforts and legal overhangs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
